<DOC>
	<DOCNO>NCT01990768</DOCNO>
	<brief_summary>Primary aim : To determine efficacy two dosing regimen TXA initiate prehospital setting patient moderate severe TBI ( GCS score ≤12 ) . Primary hypothesis : The null hypothesis prehospital administration either two dose regimen TXA patient moderate severe TBI increase proportion patient favorable long-term neurologic outcome compare placebo , base GOS-E 6 month . Secondary aim : To determine difference TXA placebo follow outcome patient moderate severe TBI treat prehospital set 2 dose regimen TXA : - Clinical outcome : ICH progression , DRS discharge 6 month , GOS-E discharge , 28-day survival , frequency neurosurgical intervention , ventilator-free , ICU-free , hospital-free day . - Safety outcome : Development seizure , cerebral ischemic event , myocardial infarction , deep venous thrombosis , pulmonary thromboembolism . - Mechanistic outcome : Alterations fibrinolysis base fibrinolytic pathway mediator degree clot lysis base TEG . Inclusion : Blunt penetrate traumatic mechanism consistent TBI prehospital GCS ≤ 12 prior administration sedative and/or paralytic agent , prehospital SBP ≥ 90 mmHg , prehospital IV intraosseous ( IO ) access , age ≥ 15yrs ( weight ≥ 50kg age unknown ) , EMS transport participate trauma center . Exclusion : GCS=3 reactive pupil , estimate time injury hospital arrival &gt; 2 hour , unknown time injury , clinical suspicion EMS seizure activity know history seizure , acute MI stroke , CPR EMS prior randomization , burn &gt; 20 % TBSA , suspect known prisoner , suspect known pregnancy , prehospital TXA give prior randomization , subject activate `` opt-out '' process require local regulatory board . A multi-center double-blind randomize control trial 3 treatment arm : - Bolus/maintenance : 1 gram IV TXA bolus prehospital setting follow 1 gram IV maintenance infusion initiate hospital arrival infuse 8 hour . - Bolus : 2 gram IV TXA bolus prehospital setting follow placebo maintenance infusion initiate hospital arrival infuse 8 hour . - Placebo : Placebo IV bolus prehospital setting follow placebo maintenance infusion initiate hospital arrival infuse 8 hour .</brief_summary>
	<brief_title>Prehospital Tranexamic Acid Use Traumatic Brain Injury</brief_title>
	<detailed_description>1 . Overview This multi-center , Phase II trial design determine Tranexamic Acid ( TXA ) initiate prehospital set improve long-term neurologic outcome compare placebo patient moderate severe TBI shock . This study protocol conduct part Resuscitation Outcomes Consortium ( ROC ) trauma center United States Canada . ROC fund National Heart Lung Blood Institute ( NHLBI ) partnership US Army Medical Research Materiel Command ( USAMRMC ) , Canadian Institutes Health Research , Heart &amp; Stroke Foundation Canada , American Heart Association ( AHA ) , Defense Research Development Canada . ROC clinical trial network focus research primarily area prehospital cardiopulmonary arrest severe traumatic injury . The mission ROC provide infrastructure project support clinical trial outcome-oriented research area cardiopulmonary arrest severe traumatic injury lead evidence-based change clinical practice . 2 . Specific Aims/Hypothesis Statement 2.1 Clinical Hypotheses Aims Specific aim 1 : To compare 6-month neurologic outcome subject bolus/maintenance arm , subject bolus arm , subject placebo arm evaluate Glasgow Outcome Scale Extended score ( GOS-E ) 6 month post-injury . Primary Hypotheses : We perform one-sided test follow null hypothesis : - Prehospital administration 1 gram intravenous ( IV ) TXA bolus follow 1 gram IV TXA maintenance infusion 8 hour ( bolus/maintenance arm ) increase proportion subject favorable neurologic outcome ( GOS-E &gt; 4 ) compare placebo , versus alternative treatment increase proportion subject favorable outcome . - Prehospital administration single 2 gram IV TXA bolus ( bolus arm ) increase proportion subject favorable neurologic outcome ( GOS-E &gt; 4 ) compare placebo , versus alternative treatment increase proportion subject favorable outcome . Specific aim 2 : To assess difference morbidity mortality measure randomization 28 day initial hospital discharge subject bolus/maintenance arm , bolus arm , placebo arm . Secondary Hypotheses : The null hypothesis difference subject bolus/maintenance arm , bolus arm , placebo arm following : absolute relative volume intracranial hemorrhage ( ICH ) progression , proportion subject ICH progression , frequency neurosurgical intervention , GOS-E measure discharge , Disability Rating Scale score ( DRS ) measure discharge 6 month , 28-day survival , ventilator-free , intensive care unit ( ICU ) -free , hospital-free day . Specific aim 3 : To assess difference adverse event measure randomization initial hospital discharge subject bolus/maintenance arm , bolus arm , placebo arm . Tertiary Hypotheses : The null hypothesis difference subject bolus/maintenance arm , bolus arm , placebo arm following : proportion subject experience seizure , cerebral ischemic event , myocardial infarction ( MI ) , deep venous thrombosis ( DVT ) , pulmonary thromboembolism ( PE ) post randomization 28 day discharge , whichever occur first . 2.2 Laboratory Hypotheses Aims Specific aim 1 : To compare coagulation profile time use kaolin activate thrombelastography ( TEG ) result subject bolus/maintenance arm , bolus arm , placebo arm . Primary hypothesis : The null hypothesis difference degree fibrinolysis assess percentage clot lysis determine 30 minute maximum amplitude reach ( LY30 ) subject bolus/maintenance arm , bolus arm , placebo arm . Specific aim 2 : To explore underlying mechanism TXA compare fibrinolytic pathway mediator activity subject bolus/maintenance arm , bolus arm , placebo arm . Secondary hypothesis : The null hypothesis change fibrinolytic pathway mediator activity measure TEG lysis time 30 minute maximum amplitude ( LY 30 ) subject bolus/maintenance arm , bolus arm , placebo arm . Specific aim 3 : To estimate association degree fibrinolysis base kaolin activate TEG result fibrinolytic pathway mediator primary secondary clinical outcome . Tertiary hypothesis : The null hypothesis association exist degree fibrinolysis fibrinolytic pathway mediator primary secondary clinical outcome . 3 . Study Enrollment EMS agency carry blind seal study drug kit . Once seal broken presence patient , patient randomize . The EMS study drug kit contain vial either 1 gram TXA , 2 gram TXA , placebo . EMS mix study drug 250 mL bag 0.9 % sodium chloride administer bolus infusion soon life-saving intervention perform . After randomization , EMS provide study drug kit ID # receive pharmacy . The hospital pharmacist obtain randomization assignment coordinate center prepare appropriate drug administer hospital . 4 . Sample Size Statistical Analysis The total sample size 1002 ( 334 per group ) , allow 80 % power detect 8.1 % absolute difference favorable long-term neurological outcome determine GOS-E 6 month injury true TXA-placebo comparison , use one-sided , level 0.1 test . Statistical analysis primary hypothesis : Modified intention-to-treat analysis use logistic regression test association estimate strength association treatment group favorable 6-month outcome ( define GOS-E &gt; 4 ) , adjustment study site . 5 . Human subject protection This study qualify exception inform consent ( EFIC ) require emergency research outline FDA regulation 21CFR50.24 . EFIC applies life-threatening situation , intervention must administer consent feasible , reasonable way identify prospectively individual risk , patient prospect benefit treatment , research could practically carry without waiver consent .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . Blunt penetrate traumatic mechanism consistent traumatic brain injury 2 . Prehospital Glasgow Coma Score ( GCS ) score ≤ 12 time prior randomization administration sedative and/or paralytic agent 3 . Prehospital systolic blood pressure ( SBP ) ≥ 90 mmHg prior randomization 4 . Prehospital intravenous ( IV ) intraosseous ( IO ) access 5 . Estimated Age ≥ 15 ( estimate weight &gt; 50 kg age unknown ) 6 . Emergency Medicine System ( EMS ) transport participate trauma center 1 . Prehospital GCS=3 reactive pupil 2 . Estimated time injury hospital arrival &gt; 2 hour 3 . Unknown time injury know reference time support estimation 4 . Clinical suspicion EMS seizure activity know history seizure , acute myocardial infarction ( MI ) stroke 5 . Cardiopulmonary resuscitation ( CPR ) EMS prior randomization 6 . Burns &gt; 20 % total body surface area ( TBSA ) 7 . Suspected known prisoner 8 . Suspected known pregnancy 9 . Prehospital TXA give prior randomization 10 . Subjects activate `` optout '' process require local regulatory board</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>tranexamic acid</keyword>
	<keyword>traumatic brain injury</keyword>
	<keyword>intracranial hemorrhage</keyword>
	<keyword>prehospital</keyword>
	<keyword>neurologic outcome</keyword>
	<keyword>glasgow outcome scale extend</keyword>
	<keyword>disability rating scale</keyword>
</DOC>